Fidelity Investments’s Cellectar Biosciences CLRB Stock Holding History

Fidelity Investments’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4	Buy	+2	New	+$5	﹤0.01%	5744
2026 Q2	–	Sell	-10	Closed	-$25	–	5595
2026 Q1	$25	Buy	+10	New	+$32	﹤0.01%	5343
2024 Q1	–	Sell	-1	Closed	-$50	–	5404
2023 Q4	$50	Sell	1 -1	-50%	-$74	﹤0.01%	5015
2023 Q3	$127	Hold	2	–	–	﹤0.01%	4828
2023 Q2	$96	Buy	+2	New	+$96	﹤0.01%	4963
2021 Q4	–	Hold	0	–	–	–	4392
2021 Q3	–	Hold	0	–	–	–	4414
2021 Q2	–	Hold	0	–	–	–	4309
2014 Q4	–	Sell	-3	Closed	-$224K	–	2795
2014 Q3	$224K	Buy	+3	New	+$259K	﹤0.01%	2733

Other funds holding CLRB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Key Financial Inc West Chester, Pennsylvania $614M AUM 14.43% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Fidelity Investments's CLRB Position: Q3 2026 in Review

Fidelity Investments opened a new position in Cellectar Biosciences (CLRB) in Q3 2026: 2 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #5744 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in CLRB as recently as Q1 2026.

Fidelity Investments first reported a position in CLRB in Q3 2014 and has held it in 6 quarters since. The position peaked at $224K in Q3 2014. 9 funds tracked by Wall St. Rank hold CLRB as of Q3 2026.

Fidelity Investments held 2 shares of Cellectar Biosciences worth $4 as of Q3 2026.
Cellectar Biosciences was a new Fidelity Investments position in Q3 2026.
Cellectar Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5744 holding.
Fidelity Investments first reported a position in Cellectar Biosciences in Q3 2014 and has held it in 6 quarters since.
Fidelity Investments's Cellectar Biosciences position peaked at $224K in Q3 2014.
9 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.